Efficacy of triple antiplatelet therapy compared with current guideline-based therapy for the prevention of recurrent stroke was evaluated in the TARDIS trial.

Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.

As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.

The results provide good evidence for the use of contact aspiration in ischemic stroke.

Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.

The co-presentation of headache at stroke onset in children may provide clues to underlying pathophysiologic mechanisms.

Psychological distress may cause changes within cells that trigger inflammation and oxidative stress, both of which are believed to increase stroke risk.

Delays related to the determination of treatment eligibility increased door-to-needle times by more than 30 minutes compared with patients with no delays.

Pulmonary embolism risk was lowest in patients with cerebral venous thromboembolism during the index hospitalization.

Neither lying flat nor sitting up appears to alter outcomes in patients presenting with acute stroke.

Among ICH survivors, 63% developed both depression and dementia during a 5-year follow-up study.